A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
John A. Ligon(University of Florida Health), John Glod(National Institutes of Health), Mary Frances Wedekind(National Cancer Institute), Amanda Carbonell(National Cancer Institute), Michael I. Barbato(Center for Drug Evaluation and Research), Xia Xu(Leidos (United States)), Josquin Moraly(Inserm), Haiyan Lei(National Cancer Institute), Cody J. Peer(National Institutes of Health), Paul S. Meltzer(National Cancer Institute), Markku Miettinen(National Institutes of Health), Jaydira Del Rivero(National Institutes of Health), King C. Chan(Leidos (United States)), Ramaprasad Srinivasan(National Cancer Institute), R. Taylor Sundby(National Cancer Institute), Seth M. Steinberg(National Institutes of Health), Richard Piekarz(Yeshiva University), Þorkell Andrésson(National Institutes of Health), Sara Zimmerman(National Institutes of Health), Eva Dombi(National Institutes of Health), Lee J. Helman(American Osteopathic Association), Karel Pacák(Endocrine Society), Brigitte C. Widemann(National Cancer Institute), William D. Figg(National Cancer Institute), Melissa Spencer(National Cancer Institute), Fernanda I. Arnaldez(MacroGenics (United States)), Lori Wiener(National Institutes of Health), Stephen Fox(Leidos (United States)), W. Marston Linehan(National Cancer Institute), Jonathan Keith Killian(GlobalFoundries (United States)), John Shern(National Cancer Institute), Naomi Taylor(National Institutes of Health)
Cited by 22
Related Papers
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817
Functionally defined therapeutic targets in diffuse intrinsic pontine glioma
|Nature Medicine|2015|711
Cushing’s Syndrome Due to Ectopic Corticotropin Secretion: Twenty Years’ Experience at the National Institutes of Health
|The Journal of Clinical Endocrinology & Metabolism|2005|711